CASEY TILLERY: Open Payments
NPI 1710227905 · MERIDIAN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$913 in 39 payments from 11 companies in 2025. Trend: 2023 $189 · 2024 $464 · 2025 $913
Food & beverage: $913
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $323 |
| AstraZeneca Pharmaceuticals LP | 3 | $138 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $102 |
| Verona Pharma, Inc. | 4 | $86 |
| Viatris Specialty LLC | 4 | $72 |
| GENZYME CORPORATION | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Philips North America LLC | 2 | $31 |
| United Therapeutics Corporation | 1 | $24 |
| Insmed, Inc. | 1 | $17 |
Products named: NUCALA, AIRSUPRA, DUPIXENT, Ohtuvayre, YUPELRI, JASCAYD, TRELEGY ELLIPTA, OFEV.
Industry payments across MS — which companies pay providers there.
